home / stock / bbio / bbio news

BBIO News and Press, BridgeBio Pharma Inc. From 03/29/23

Stock Information
Company Name: BridgeBio Pharma Inc.
Stock Symbol: BBIO
Market: NYSE
Website: bridgebio.com
Menu
BBIO BBIO Quote BBIO Short BBIO News BBIO Articles BBIO Message Board
Get BBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
BBIO - BridgeBio jumps 18% amid rumors about decision to pull out of conference

2023-03-29 12:12:50 ET BridgeBio Pharma ( NASDAQ: BBIO ), a potential buyout target, added ~18% on Wednesday, recording the second-best intraday gain for the year, amid market rumors that the company has decided to pull out of a conference next week. BridgeBio ( BBIO...
BBIO - IOVA, BBIO and IREN are among after hour movers

2023-03-24 17:28:03 ET Gainers: BridgeBio Pharma ( BBIO ) +14% . Iovance Biotherapeutics ( IOVA ) +10% . Iris Energy  ( IREN ) +5% . Alphabet ( GOOGL ) +4% . Zions Bancorporation  ( ZION ) +3% . Losers: CRISPR T...

BBIO - BridgeBio jumps on report of takeover interest

2023-03-24 17:06:23 ET BridgeBio Pharma rose 10% in regular trading and jumped another 14% in after hours on a report that the developer of treatments for genetic diseases is garnering takeover interest from big pharma companies. Some large drug companies are evaluating a po...

BBIO - Dermata, GH Research top healthcare gainers; BridgeBio, Cidara among losers

2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...
BBIO - BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors

2023-03-23 08:29:24 ET BridgeBio Pharma ( NASDAQ: BBIO ) said the first patient with non-small cell lung cancer (NSCLC) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's ( NYSE: BMY ) Opdivo (nivolumab) to treat advanced solid tumors with KR...

BBIO - BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mu...

BBIO - SPLK, HA and PRPL are among after hour movers

2023-03-21 16:57:51 ET Gainers: Maxpro Capital Acquisition  ( JMAC ) +31% . Telesis Bio ( TBIO ) +10% . BridgeBio Pharma ( BBIO ) +4% . Hawaiian Holdings ( HA ) +2% . ProFrac Holding  ( ACDC ) +2% . Losers: Adap...
BBIO - BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (?DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺ DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I patients - BridgeBio also shared 15-month results from its ongoing Pha...

BBIO - BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (?DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an oral pr...

BBIO - Hot Stocks: RIGL, KFY gain on earnings; DSEY surges on going-private deal; SHLS, BBIO slide

2023-03-08 11:54:50 ET During Wednesday's midday trading, the major U.S. equity indexes were mixed, as Wall Street tried to recover following hawkish comments by Federal Reserve Chairman Jerome Powell the day before. Looking at the individual stocks, Korn Ferry ( NYSE: KFY )...
Previous 10 Next 10